title: Constitutive activation of Stat3 signaling abrogates apoptosis in squamous cell carcinogenesis in vivo.
abstract: Field cancerization predisposes the upper aerodigestive tract mucosa to the formation of multiple primary tumors, when exposed to environmental carcinogens. Up-regulation of epidermal growth factor receptor occurs early in squamous cell carcinogenesis and is critical for the loss of growth control in a variety of human cancers, including head and neck squamous cell carcinomas. In these tumor cells in culture, epidermal growth factor receptor stimulation initiates signaling via persistent activation of selective STAT proteins. To determine the timing of Stat3 activation in head and neck carcinogenesis, we studied the expression and constitutive activation of Stat3 in tumors and normal mucosa from patients with head and neck cancer compared with mucosa from controls without cancer. Stat3 was up-regulated and constitutively activated in both primary human head and neck tumors as well as in normal mucosa from these cancer patients compared with control normal mucosa from patients without cancer. In vivo liposome-mediated gene therapy with a Stat3 antisense plasmid efficiently inhibited Stat3 activation, increased tumor cell apoptosis, and decreased Bcl-x(L) expression in a head and neck xenograft model. These findings provide evidence that constitutively activated Stat3 is an early event in head and neck carcinogenesis that contributes to the loss of growth control by an anti-apoptotic mechanism.
authors.affiliation: Department of Otolaryngology, University of Pittsburgh School of Medicine and University of Pittsburgh Cancer Institute, Pittsburgh, PA 15213, USA. jgrandis+@pitt.edu
authors.forename: J R
authors.initials: JR
authors.lastname: Grandis
authors.forename: S D
authors.initials: SD
authors.lastname: Drenning
authors.forename: Q
authors.initials: Q
authors.lastname: Zeng
authors.forename: S C
authors.initials: SC
authors.lastname: Watkins
authors.forename: M F
authors.initials: MF
authors.lastname: Melhem
authors.forename: S
authors.initials: S
authors.lastname: Endo
authors.forename: D E
authors.initials: DE
authors.lastname: Johnson
authors.forename: L
authors.initials: L
authors.lastname: Huang
authors.forename: Y
authors.initials: Y
authors.lastname: He
authors.forename: J D
authors.initials: JD
authors.lastname: Kim
mesh_terms: D000818:Animals; D017209:Apoptosis; D002294:Carcinoma, Squamous Cell / Q000235:genetics / Q000473:pathology* / Q000628:therapy; D004268:DNA-Binding Proteins / Q000235:genetics / Q000378:metabolism*; D066246:ErbB Receptors / Q000378:metabolism; D005260:Female; D015316:Genetic Therapy; D006258:Head and Neck Neoplasms / Q000235:genetics / Q000473:pathology* / Q000628:therapy; D006801:Humans; D008081:Liposomes; D051379:Mice; D008819:Mice, Nude; D009368:Neoplasm Transplantation; D016376:Oligonucleotides, Antisense / Q000494:pharmacology; D050796:STAT3 Transcription Factor; D015398:Signal Transduction; D015534:Trans-Activators / Q000235:genetics / Q000378:metabolism*; D015291:Transforming Growth Factors / Q000378:metabolism; D014407:Tumor Cells, Cultured
chemical_list: D004268:DNA-Binding Proteins; D008081:Liposomes; D016376:Oligonucleotides, Antisense; D050796:STAT3 Transcription Factor; C494086:STAT3 protein, human; C494087:Stat3 protein, mouse; D015534:Trans-Activators; D015291:Transforming Growth Factors; D066246:ErbB Receptors